Abstract: The present invention provides compositions, systems, kits, and methods for expressing at least one therapeutic protein or biologically active nucleic acid molecule in a subject. In certain embodiments, the subject is first administered a composition comprising polycationic structures that is free, or essentially free, of nucleic acid molecules, and then (e.g., 1-30 minutes later) is administered a composition comprising a plurality of one or more non-viral expression vectors that encode at least one therapeutic protein (e.g., at least one anti-SARS-CoV-2 antibody, multiple different antibodies, an ACE2 protein, or human growth hormone) or a biologically active nucleic acid molecule.

Abstract: Provided herein are compositions relating to tissue-specific antigens, and methods for identifying tissue-specific antigens. Also provided herein are pharmaceutical compositions and methods of treatment that relate to tissue-specific antigens.

Abstract: A method for assessing responsiveness of a subject to a treatment comprising T cells expressing a bivalent BCMA-targeting chimeric antigen receptor (CAR), comprising administering to the subject the T cells, and assessing the responsiveness of the subject to the treatment based on time length the subject maintains minimal residual disease (MRD) negative status.

Abstract: This disclosure provides genetically engineered immune cells that express an anti-GD2 chimeric antigen receptor, methods of generating these cells, and methods of treating tumors using the genetically engineered cells.

Abstract: The compositions and methods described herein are topically applied to the skin with negligible or no skin irritation and can direct or prevent transport through the skin. The compositions contain neat ionic liquids, optionally in combination with a drug to be delivered. In a preferred embodiment, the compositions increase transdermal transport of the drug to be delivered. In some embodiments, the compositions disrupt bacterial biofilms. This is particularly beneficial in the treatment of antibiotic resistant skin infections. In other embodiments, the compositions direct delivery within the skin. In still other embodiments, the compositions prevent transfer of substances through the stratum corneum. The disclosed compositions and methods can be tuned and modified such that they can be used to treat or prevent a variety of different diseases and disorders.

Abstract: The present application relates to a compound having the formula (I) A-L-B wherein A is represented by (AA), L is a bond or a self-immolative spacer; and B is represented by (BB) or (CC). The compound is capable of releasing molecular cargo in the presence of a reductase and is thus suitable for diagnosing or quantifying the activity of the reductase and for treating, ameliorating, preventing or diagnosing a disorder selected from a neoplastic disorder; atherosclerosis; an autoimmune disorder; an inflammatory disease; a chronic inflammatory autoimmune disease; ischaemia; and reperfusion injury.

Abstract: The present invention relates to a siRNA drug, a pharmaceutical composition, a siRNA-small molecule drug conjugate, and the application thereof. The siRNA molecules block the life cycle of virus replication by targeting and inhibiting the expression of key genes for influenza viruses, reduce viral infection, and ultimately clear the viruses. The present invention provides a drug based on the siRNA. The drug can be atomized into liquid droplets through an atomizing device, and the liquid droplets reach the lower respiratory tract and the lung by inhalation, so as to inhibit the replication of the influenza viruses. The pharmaceutical composition of the present invention can exert a synergistic antiviral effect through different mechanisms of action.

Abstract: Provided herein are bifunctional compounds having the chemical structure I: PTM-L-CLM??(I); or pharmaceutically acceptable salts thereof, which find utility as modulators of Rapidly Accelerated Fibrosarcoma (Raf, such as c-Raf, A-Raf, and/or B-RAF) and are useful in the treatment of a variety of Raf mediated conditions or diseases, such as cancer, specifically lung cancer, skin cancer, or colorectal cancer.

Abstract: Provided herein are bifunctional compounds, which find utility as modulators of Rapidly Accelerated Fibrosarcoma (Raf, such as c-Raf, A-Raf, and/or B-RAF).

Abstract: Compounds and compositions are disclosed in which a quaternized drug unit is linked to a targeting ligand unit from which a tertiary amine-containing drug is released at the targeted site of action. Methods for treating diseases characterized by the targeted abnormal cells, such as cancer or an autoimmune disease using the compounds and compositions of the invention are also disclosed.

Abstract: This disclosure relates generally to Neisseria surface moieties. More particularly, the present disclosure relates to oligosaccharides corresponding to Neisseria lipooligosaccharides and to chimeric molecules comprising these moieties for eliciting an immune response to Neisseria organisms and/or for treating or inhibiting the development of Neisseria infections.

Abstract: The present application relates to methods and uses of conjugates comprising antitumor agents (e.g., chemotherapeutic agents) conjugated to peptide compounds targeting Sortilin-expressing cancer stem cells (CSCs), in embodiments for the treatment of poor prognosis cancers refractory to standard antitumor therapies associated the presence of Sortilin-expressing CSCs, and for preventing or treating cancer relapse or recurrence.

Abstract: The present disclosure relates generally to the field of cancer immunotherapy. More particularly, the present disclosure provides antibody recruitment molecules, pharmaceutical compositions comprising same and kits comprising same. The present disclosure also provides methods of treating cancer using the antibody recruitment molecules in combination with oncolytic virus therapy, and methods for enhancing the efficacy and/or reducing the toxicity of the oncolytic virus therapy.

Abstract: Bone-targeting therapeutic compounds and pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising a bone-targeting therapeutic compound; processes for preparing bone-targeting therapeutic compounds; and therapeutic methods to treat bone defects.

Abstract: Compositions and methods for modulating antibody activity are disclosed.

Abstract: Compositions and methods for the treatment of viral infections include conjugates containing inhibitors of viral neuraminidase (e.g., zanamivir, peramivir, or analogs thereof) linked to an Fc monomer, an Fc domain, and Fc-binding peptide, an albumin protein, or albumin-binding peptide. In particular, conjugates can be used in the treatment of viral infections (e.g., influenza viral infections).

Abstract: The invention provides a one-step process for preparing a cell-binding agent cytotoxic agent conjugate comprising contacting a cell-binding agent with a cytotoxic agent to form a first mixture comprising the cell-binding agent and the cytotoxic agent and contacting the first mixture comprising the cell-binding agent and the cytotoxic agent with a bifunctional crosslinking reagent, which provides a linker, in a solution having a pH of about 4 to about 9 to provide a second mixture comprising the cell-binding agent cytotoxic agent conjugate, wherein the cell-binding agent is chemically coupled through the linker to the cytotoxic agent, free cytotoxic agent, and reaction by-products. The second mixture is then optionally subjected to purification to provide a purified cell-binding agent cytotoxic agent conjugate.

Abstract: The present invention provides antibodies and antibody-drug conjugates that bind to the extra domain B splice variant of fibronectin 1 and methods for preparing and using the same.

Abstract: Antibody-drug conjugates (ADCs) are described, comprising anti-TM4SF1 antibodies, antigen-binding fragments thereof, a linker and a drug. The drug is an inhibitor of tubulin polymerization. Methods of use of the ADCs are also described.

Abstract: The invention relates generally to proteins comprising a recombinant Siglec extracellular domain (ECD), or a functional fragment or variant thereof, optionally containing a mutation that reduces sialic acid binding activity and/or conjugated to a serum half-life enhancer. The invention further relates to methods of using the proteins for treating an inflammatory disorder and/or an autoimmune disorder.

Abstract: The application relates to prodrugs comprising a drug molecule connected by a protease-cleavable peptide linker to a binder, which reversibly inhibits a biological activity of the drug molecule, and to the inhibitory binders themselves. Also described are nucleic acids encoding the recombinant proteins described herein, and methods of making said recombinant proteins, as well as methods of treatment and medical uses of the recombinant proteins.

Abstract: Provided for herein is a polynucleotide-modified bioconjugate comprising a substrate such as an antibody or bead linked to a conjugate component via a nucleic acid linker. Also provided are methods of making and using such bioconjugates. Conjugation methods for creating the bioconjugate are stable, not chemically harsh, and efficient enough that post-conjugation purification may not be required. Further this disclosure provides for reducing the logistic overheads related to product lines by eliminating the need for many unique linkers per conjugation pair.

Abstract: A method for forming peptide-coated nanoparticles. The nanoparticles are polylactic co-glycol polymer (PLGA). The coatings are self-assembled layers selected from RGDFFF (SEQ ID NO: 1); NGRFFF (SEQ ID NO: 2), EKHFFF (SEQ ID NO: 3) or TPP-KFF. A cargo molecule, such as a dye or a therapeutic may be bound to the nanoparticle.

Abstract: The present invention provides quaternary ammonium cyclodextrin and a preparation method and uses thereof, as well as a silver nanoparticle-cyclodextrin complex and a preparation method and uses thereof. The quaternary ammonium cyclodextrin of the present invention is introduced with an amine group and quaternary ammonium groups, while retaining the special structure and properties of cyclodextrin itself. The amine group contained in the structure plays a role in reducing and complexing Ag+ in the synthesis of AgNPs, and plays a certain role in stabilizing nanoparticles and forming a complex in combination with quaternary ammonium groups.

Abstract: The present invention concerns a polymeric material for the production of a non-viral nanoparticle. The polymeric material comprises (i) a hydrophilic linear polymer having a first end and a second end, (iii) a cross-linkable cationic polymer covalently bonded to the first end of the hydrophilic linear polymer, and (iii) at least one targeting/penetrating peptide covalently associated to the second end of the hydrophilic linear polymer. Also disclosed herein are nanoparticles produced with these polymeric material, processes for making the polymeric material and the nanoparticles as well as use of the nanoparticles.

Abstract: Novel 5? untranslated region (UTR)-targeting gene knock-in (KI) compositions and methods of use are disclosed. The gene KI compositions and methods exploit homology-independent targeted integration (HITI)-mediated insertion of a wild-type coding sequence (CDS) into the 5? UTR upstream of a translation initiation element of a mutated variant of the wild-type gene. The 5? UTR-targeting gene KI therapy compositions and methods provide safer and more efficient gene insertion compared to other gene therapy approaches.

Abstract: A gene therapy DNA vector based on the VTvaf17 gene therapy DNA vector carrying a target gene selected from the group of genes COL1A1, COL1A2, P4HA1, P4HA2, COL7A1, CLCA2, ELN, PLOD1 to increase the expression level of this target gene in humans and animals. Moreover, the gene therapy DNA vector VTvaf17-COL1A1 or VTvaf17-COL1A2 or VTvaf17-P4HA1 or VTvaf17-P4HA2 or VTvaf17-COL7A1 or VTvaf17-CLCA2 or VTvaf17-ELN or VTvaf17-PLOD1 has the nucleotide sequence SEQ ID NO. SEQ ID No. 3 or SEQ ID No. 4 or SEQ ID No. 5 or SEQ ID No. 6 or SEQ ID No. 7 or SEQ ID No. 8, respectively. The DNA vector contains no nucleotide sequences of viral origin and no antibiotic resistance genes, providing the possibility of its safe use for genetic therapy in humans and animals.

Abstract: The present invention relates in part to nucleic acids, including nucleic acids encoding proteins, therapeutics and cosmetics comprising nucleic acids, methods for delivering nucleic acids to cells, tissues, organs, and patients, methods for inducing cells to express proteins using nucleic acids, methods, kits and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, therapeutics, and cosmetics produced using these methods, kits, and devices.

Abstract: Synthetic nucleic acids are described that can be used for astrocyte-directed expression of heterologous nucleotide sequences. Also described are methods of using the same for astrocyte-directed expression of such nucleotide sequences for the treatment of neurodegenerative diseases.

Abstract: The present disclosure provides a method of modifying a mutant dystrophin gene in the genome of a cell. The present disclosure further provides compositions and kits for modifying a mutant dystrophin gene in the genome of a cell.

Abstract: The invention provides a 7-ethyl-10-hydroxycamptothecin drug precursor with fluorescence activity and a preparation method and use thereof. The method involves that a carboxyl group of a boron dipyrromethene dye molecule is condensed with a hydroxyl group at the 10 position of 7-ethyl-10-hydroxycamptothecin, yielding a 7-ethyl-10-hydroxy-camptothecin drug precursor (BDP-SN38) with fluorescent activity. BDP-SN38 shows good solubility and stability in most pharmaceutically acceptable solvents. Compared with SN38, BDP-SN38 exhibits comparable antitumor activity, has high tumor uptake capacity, and produces strong green fluorescence with the excitation of visible light, thus providing fluorescence-guided bioimaging and further treatment of residual tumors after drug treatment, and having good application prospects in the research of integrated diagnosis and treatment and effective tumor treatment.

Abstract: A composition, containing indocyanine green (a), and histidine (b). A weight ratio of histidine (b)/indocyanine green (a) is greater than 0.05. A kit for preparing the composition, containing in separate compartments the indocyanine green (a), and an aqueous solution including the histidine (b). The composition is a medicament or a diagnostic agent.

Abstract: An ophthalmic composition comprising Indigo Carmine, or Indigo Carmine and Trypan Blue, for identification of intraocular structures and membranes within the eye, and methods of delivering and using the same, for surgical treatments of the eye, including glaucoma and cataract surgery.

Abstract: A method of monitoring viability of stem cell-derived cells used in stem cell therapy comprises introducing one or more stem cell-derived cells to a cell culture media, introducing one or more nanoprobes to the cell culture media, whereby the one or more stem cell-derived cells are transfected with the one or more nanoprobes, and detecting an optical signal from the one or more nanoprobes after transfection. The method may further comprise introducing the one or more transfected stem cell-derived cells to a subject and detecting the optical signal from the one or more nanoprobes in vivo. The one or more stem cell-derived cells may include a stem cell.

Abstract: A fluorine-containing compound represented by Formula (1) or Formula (2) (R1, R2, and R3 in Formula (1) and R4 and R5 in Formula (2) each represent a C1-10 alkyl group unsubstituted or substituted with a substituent containing no fluorine atoms, and X1 in Formula (1) and X2 and X3 in Formula (2) are any of Formulae (3-1) to (3-4).

Abstract: A molecular probe includes the following formula: P-L-C wherein P is a EDB-FN targeting peptide, C is a contrast agent; and L is a non-peptide linker that covalently links the peptide to the contrast agent.

Abstract: A biocompatible radionuclide-containing composition comprising: (i) a radionuclide-containing core, which includes complexed or uncomplexed radionuclide atoms; and (ii) a carrier encapsulating the radionuclide-containing core, wherein the carrier may be attached to a targeting moiety that can selectively transport the composition to a specific cell type when introduced into an organism, or the carrier may be attached to a moiety that evades an immune system of an organism. Also described is a method of treating cancer in a subject by administering to the subject a pharmaceutically effective amount of the composition described above. Also described is a method of treating an infection in a subject by administering to the subject a pharmaceutically effective amount of the composition described above. Also described is a method of imaging biological tissue in a subject by administering the composition to the subject and imaging biological tissue in the subject by a nuclear medicine imaging technique.

Abstract: A fluorine-18-labeled positron emission tomography (PET) radiotracer for diagnosing neuroinflammation, stroke or cerebral infarction and a method for using the radiotracer are provided.

Abstract: The present disclosure provides compounds, complexes, compositions, and methods for the detection of cancer. Specifically, the compounds, complexes, compositions of the present technology include pH (low) insertion peptides. Also disclosed herein are methods of using the complexes and compositions of the present technology in diagnostic imaging to detect cancer in a subject.

Abstract: The present invention covers compounds of general formula (I): [(C)n-L]-(V)m (I) where C is a chelator and n>1, L is a multi-functional linker moiety comprising multiple functional groups for the covalent attachment of chelator such as a polyamine or polyacid-containing backbone or amino acid containing polymer comprising side-chains with amino, thiol or carboxylic acid moieties such as lysine, cysteine or glutamic acid and V is a tissue targeting moiety where m=1-5 which preferentially coupled through a coupling moiety to either the multifunctional linker moiety L or directly to the chelator moiety C, and stereoisomers, tautomers, N-oxides, hydrates, solvates, and salts thereof, and mixtures of same.

Abstract: Methods for producing allograft tissue by applying an antimicrobial solution to allograft tissue. The antimicrobial solution exhibits antimicrobial activity to make allograft resistant to microbial organisms, such as bacterium. Surface-modified tissue grafts prepared by these methods are also disclosed.

Abstract: The invention relates to a method for disinfecting, in particular sterilizing, an article in a package, in which an article packaged in a package is provided, wherein the package is impermeable to germs, in particular bacteria and/or viruses, and wherein the package has a gas-permeable portion, in which a reactive gas, in particular a reactive gas stream, is generated by means of a plasma source, and in which the gas-permeable portion of the package is exposed to the reactive gas, in particular the reactive gas stream. The invention further relates to a method for disinfecting, in particular sterilizing, an article in a package, in which an article packaged in a package is provided, the package being impermeable to germs, in particular bacteria and/or viruses, in which electrical discharges are generated in a discharge region, and in which the package with the article packaged therein is transported through the discharge region.

Abstract: The present invention relates to a reusable integrated light-activated sterilization system, as well as to a method of preparing the sterilization system. Additionally, the present invention relates to a catheter cap including the reusable light-activated sterilization system.

Abstract: An object of the present invention is to provide an ultraviolet light irradiation system and an ultraviolet light irradiation method which can perceive a state of a region where ultraviolet light is irradiated to output/block the ultraviolet light. An ultraviolet light irradiation system 301 according to the present invention includes an ultraviolet light source unit 11 that produces ultraviolet light, an N (N is a natural number) irradiation unit 13 that irradiates an irradiation target region Ar with the ultraviolet light, a sensor unit 31 that detects whether or not an object that should avoid exposure is present in the irradiation target region Ar, and a blocking unit 30 that stops, in a case where the object that should avoid exposure is present in the irradiation target region Ar, irradiation of the ultraviolet light from the irradiation unit 13 to the irradiation target region Ar.

Abstract: A sump of a water coalescing filter includes a sump space, a drain coupled to the sump space, a water sensor coupled to the sump space to periodically activate the drain and at least one UVC light source illuminating the water sensor within the sump space. An anti-biofouling reservoir for an industrial fluid includes a reservoir space and sterilization zone or sump space as a lower portion thereof, and preferably a drain is coupled to the sterilization zone, a water sensor coupled to the sterilization zone that is used to periodically activate the drain and at least one UVC light source illuminating the fluid within the sterilization zone. An anti-biofouling water in fuel sensor includes a sensor body having a pair of spaced probes and at least one UVC light source configured for illuminating the probes.

Abstract: A method for treating foul odors. A chemical solution is administered to the area to be treated. The chemical solution includes: potassium iodine, zinc sulfate and magnesium sulfate. In a preferred embodiment the chemical solution is diluted in water and applied to an area needing treatment.

Abstract: An active oxygen supply device comprising: a housing having at least one opening; an ozone generator located inside the housing; a means for generating an airflow comprising ozone generated inside the housing by the ozone generator, flowing toward the opening and flowing out of the housing through the opening; and an ultraviolet light source arranged so that the airflow comprising the ozone and flowing out of the housing through the opening can be irradiated with ultraviolet rays, wherein the ultraviolet light source decomposes the ozone in the airflow to generate active oxygen, and the airflow comprising the active oxygen generated by irradiating the airflow comprising the ozone with the ultraviolet rays is supplied to an object to be treated outside the housing.

Abstract: An information processing system includes: a terminal used by a user; a detection unit that detects at least one of a position of contact by the user and a position in which droplets of saliva of the user are attached, in the terminal; and an identification unit that identifies a sanitization part to be sanitized of the terminal, on the basis of the at least one of the positions. According to such an information processing system, it is possible to properly identify the part to be sanitized in an operation terminal.

Abstract: In response to a person touching a portion indicated by reference sign 1A on a desk 91 installed in a room R, for example, a control device 60 identifies this touched area as an identified area 80 that has been contaminated by the person. In this case, the control device 60 controls a drive mechanism 30 to direct a light source 20 to this identified area 80. The area touched by the person in the room R is thus UV-irradiated and sterilized.

Abstract: A system may automatically conduct hygiene cycles for a confined space such an interior space of a box suitable for storing and/or carrying packaged food. The system may include a hygiene device that can be attached to the box to conduct the hygiene cycles. The system may also automatically collect information related to the hygiene cycles and transmit the collected information to a network.